Trial Outcomes & Findings for Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial (NCT NCT04667481)
NCT ID: NCT04667481
Last Updated: 2024-02-12
Results Overview
Will be determined with all-cause intervention discontinuation rate, which is the proportion of all intervention participants who permanently stop the intervention prior to week 24 for any reason.
COMPLETED
NA
27 participants
Week 24
2024-02-12
Participant Flow
Participant milestones
| Measure |
Arm I (Aerobic Exercise)
Patients participate in AE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and RE sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
Aerobic Exercise Intervention: Participate in aerobic exercise intervention
Resistance Exercise Intervention: Participate in resistance exercise intervention
Quality-of-Life Assessment: Ancillary studies
|
Arm II (Resistance Exercise)
Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
Aerobic Exercise Intervention: Participate in aerobic exercise intervention
Resistance Exercise Intervention: Participate in resistance exercise intervention
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
Control Group (Digital Exercise Interventions)
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
|---|---|---|---|
|
Overall Study
STARTED
|
9
|
9
|
9
|
|
Overall Study
COMPLETED
|
9
|
8
|
8
|
|
Overall Study
NOT COMPLETED
|
0
|
1
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial
Baseline characteristics by cohort
| Measure |
Arm I (Aerobic Exercise)
n=9 Participants
Patients participate in AE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and RE sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
Aerobic Exercise Intervention: Participate in aerobic exercise intervention
Resistance Exercise Intervention: Participate in resistance exercise intervention
Quality-of-Life Assessment: Ancillary studies
|
Arm II (Resistance Exercise)
n=9 Participants
Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
Aerobic Exercise Intervention: Participate in aerobic exercise intervention
Resistance Exercise Intervention: Participate in resistance exercise intervention
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
Control Group (Digital Exercise Interventions)
n=9 Participants
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
Total
n=27 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
8 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
23 Participants
n=7 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
4 Participants
n=7 Participants
|
|
Age, Continuous
|
58.9 years
STANDARD_DEVIATION 5.7 • n=99 Participants
|
48.9 years
STANDARD_DEVIATION 11.7 • n=107 Participants
|
56.6 years
STANDARD_DEVIATION 11.6 • n=206 Participants
|
54.8 years
STANDARD_DEVIATION 10.6 • n=7 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
27 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
9 Participants
n=99 Participants
|
9 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
27 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
4 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Race (NIH/OMB)
White
|
6 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
20 Participants
n=7 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
PRIMARY outcome
Timeframe: Week 24Will be determined with all-cause intervention discontinuation rate, which is the proportion of all intervention participants who permanently stop the intervention prior to week 24 for any reason.
Outcome measures
| Measure |
Arm I: Aerobic Exercise
n=9 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
|
Arm II: Resistance Exercise
n=9 Participants
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
|
Control Group
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
|---|---|---|---|
|
Intervention Feasibility
Discontinued Intervention
|
1 Participants
|
3 Participants
|
—
|
|
Intervention Feasibility
Completed Intervention
|
8 Participants
|
6 Participants
|
—
|
SECONDARY outcome
Timeframe: Up to 24 weeksPopulation: Only adverse events probably or definitely attributed to study procedures are counted.
Intervention safety will be determined by reviewing and quantifying the number of adverse events (mild, moderate, or severe), serious adverse events, and by reviewing the type and severity of adverse events attributed to study procedures among each study group.
Outcome measures
| Measure |
Arm I: Aerobic Exercise
n=9 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
|
Arm II: Resistance Exercise
n=9 Participants
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
|
Control Group
n=9 Participants
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
|---|---|---|---|
|
Intervention Safety: Adverse Events
Count of participants with at least one AE
|
2 Participants
|
3 Participants
|
0 Participants
|
|
Intervention Safety: Adverse Events
Gastrointestinal/Digestive
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Intervention Safety: Adverse Events
Respiratory
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Intervention Safety: Adverse Events
Skin
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Intervention Safety: Adverse Events
Musculoskeletal
|
2 Participants
|
3 Participants
|
0 Participants
|
|
Intervention Safety: Adverse Events
Nervous System/Neurological
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Intervention Safety: Adverse Events
Psychiatric
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Intervention Safety: Adverse Events
Injuries
|
1 Participants
|
2 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Up to 24 weeksStudy feasibility will be measured by calculating recruitment rates (proportion of enrolled participants to all individuals approached), and loss to follow-up (proportion of participants who do not complete post-intervention assessments). A benchmark to determine feasibility is \< 40% loss to follow-up.
Outcome measures
| Measure |
Arm I: Aerobic Exercise
n=27 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
|
Arm II: Resistance Exercise
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
|
Control Group
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
|---|---|---|---|
|
Study Feasibility
Did not complete endpoint assessment
|
2 Participants
|
—
|
—
|
|
Study Feasibility
Completed endpoint assessment
|
25 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 24 weeksAcceptability will be measured with qualitative, open-ended to assess participant experience in the intervention and gather information for improving the protocol in future studies. Of particular attention will be the tolerability of a remote, home-based exercise intervention with a semi supervised format.
Outcome measures
| Measure |
Arm I: Aerobic Exercise
n=9 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
|
Arm II: Resistance Exercise
n=9 Participants
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
|
Control Group
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
|---|---|---|---|
|
Intervention Acceptability
Satisfied with sessions
|
9 Participants
|
9 Participants
|
—
|
|
Intervention Acceptability
Exercise Provided Enough Challenge
|
9 Participants
|
9 Participants
|
—
|
|
Intervention Acceptability
Desired more personalized instruction
|
3 Participants
|
4 Participants
|
—
|
SECONDARY outcome
Timeframe: Up to 24 weeksThe Rating of Perceived Exertion (RPE) scale asks respondents to rate the intensity of exercise on a 1-10 scale, with higher values representing greater perceived exertion (1 = Very Light Activity, 10 = Maximum Possible Exertion). The measure has been validated for estimating both aerobic and resistance exercise exertion levels, providing a standard measure across intervention modalities. The average RPE for full-intensity sessions (the first few weeks involve an increasing RPE across sessions) will be calculated for each participant.
Outcome measures
| Measure |
Arm I: Aerobic Exercise
n=9 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
|
Arm II: Resistance Exercise
n=9 Participants
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
|
Control Group
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
|---|---|---|---|
|
Intervention Session Intensity
|
5.86 units on a scale
Standard Deviation 1.37
|
5.60 units on a scale
Standard Deviation 1.62
|
—
|
SECONDARY outcome
Timeframe: Up to 24 weeksParticipants will complete an RPE rating after each session. These ratings will be used to calculate adherence rate for each participant. A session with an RPE that is at or above the intended RPE will be considered adherent. The number of adherent sessions will be divided by the total number of sessions, whether the session was attended or not. The participant adherence rates will be averaged to find a mean adherence rate per participant.
Outcome measures
| Measure |
Arm I: Aerobic Exercise
n=9 Participants
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
|
Arm II: Resistance Exercise
n=9 Participants
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
|
Control Group
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
|---|---|---|---|
|
Intervention Adherence
|
52.8 percentage of adherent sessions
Standard Deviation 31.0
|
40.7 percentage of adherent sessions
Standard Deviation 32.2
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksThis is operationalized as maximal exercise capacity, which is ascertained by measuring peak oxygen consumption (volume oxygen \[VO2\] peak) during cardiopulmonary exercise testing (CPET). All CPETs will be administered by a trained exercise physiologist using the Modified Bruce protocol, an appropriate testing paradigm for people with reduced physical functioning. This procedure will estimate the VO2 (absolute).
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksThis is operationalized as maximal exercise capacity, which is ascertained by measuring peak oxygen consumption (volume oxygen \[VO2\] peak) during cardiopulmonary exercise testing (CPET). All CPETs will be administered by a trained exercise physiologist using the Modified Bruce protocol, an appropriate testing paradigm for people with reduced physical functioning. This procedure will estimate the VO2 (relative to bodyweight).
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksSubmaximal exercise capacity, also considered functional capacity, will be determined with the six minute walk test (6MWT), which measures the distance a person can walk in six minutes (6MWD). A widely used measure of submaximal exercise capacity, the 6MWT will be administered at all study timepoints to evaluate intervention response.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksPrior to the measurement of body weight, participants will be instructed to remove heavy clothing and empty pockets of their contents. Weight will be measured to the nearest one-tenth kg with a calibrated balance beam or digital scale.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksHip circumference will be measured to the nearest one-tenth cm.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksHeight will be measured while the participant stands without shoes using a wall-mounted stadiometer to the nearest one-tenth cm.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksSubcutaneous (SQ) fat and visceral adipose tissue (VAT) will be assessed via abdominal MRI. For analysis, fat depots will be separated into abdominal SQ fat and VAT which will be further segmented into intraperitoneal (IP) and retroperitoneal (RP) fat using commercially available software. SQ fat will be defined as the fat outside the muscular abdominal wall; IP fat as fat within the mesentery and omentum bounded anteriorly and laterally by the abdominal wall and posteriorly by a curved line drawn between the kidneys; RP fat as the remaining fat. Adipose tissues will be segmented and colored from other tissues based on pixel intensity and known divisions of tissue planes. The MRI analyst, blinded to participant characteristics, will correct any misidentified fat or non-fat regions using manual tools provided within the software. To calculate each of the compartmental fat deposits, the number of subpixels within each fat compartment.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksThe ratio of thigh IMF to skeletal muscle (SM) will be ascertained via magnetic resonance imaging (MRI) by trained MRI technologists. Participants will undergo a screening process with the MRI technologist to ensure that eligibility criteria for MRI scans are met. Participants will then change into a hospital gown and enter the MRI scanner. In this longitudinal assessment of IMF, the MRI technologist will be instructed to match participant scan positions across time by matching the current scan position with the participant's previous scan position, recorded at the timepoint prior. MRI analysts will quantitate total and compartment amounts of muscle and adipose tissue using cross-sectional areas of thigh skeletal muscle (SM) and IMF using commercially available software. Thigh IMF area will be calculated as the number of fat pixels within the thigh musculature multiplied by the pixel surface area.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksWaist circumference will be measured to the nearest one-tenth cm.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksThe Short Form Health Survey-36 (SF-36) is a widely used self-report measure of quality of life and health status. Comprised of 36 multiple choice questions, the SF-36 queries general perceptions a participant has about their health, as well as limitations to physical activity, physical health problems, mental health problems, pain, and energy/fatigue. The SF-36 is used across health research domains, and in breast cancer has been validated as a reliable longitudinal monitor of quality of life.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksTime spent engaging in physical activity will be measured with the Physical Activity Recall Interview. The PAR assesses time spent in physical activity over the past 7 days.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksParticipants' perception of their current well-being will be assessed with the 28-item 5-point Likert scale Functional Assessment of Cancer Therapy (FACT)-General. The FACT-G contains 4 subscales measuring physical, social, emotional, and functional well-being and has been validated for reliably measuring well-being in cancer patients.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksTime spent engaging in sedentary lifestyle behaviors will be measured with the self-administered Sedentary Behaviors Questionnaire (SBQ). The SBQ measures the minutes spent participating in 9 different sedentary behaviors per "typical" weekday and weekend day.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 24 weeksThe Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale is a 13-item scale originally developed for and widely used to assess cancer-related fatigue. The FACIT-Fatigue scale measures severity (i.e., "I feel fatigued"; "I feel weak all over") and impact of fatigue (e.g., "I need help doing my usual activities"; "I have to limit my social activity because I am tired") over the past week, with responses scored on a 5-point scale, from 0 "not at all" to 4 "very much." The FACIT-Fatigue scale has excellent psychometric properties and a focus on physical aspects of fatigue.
Outcome measures
Outcome data not reported
Adverse Events
Arm I: Aerobic Exercise
Arm II: Resistance Exercise
Control Group
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Arm I: Aerobic Exercise
n=9 participants at risk
ARM I: Patients participate in aerobic exercise (AE) sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and resistance exercise (RE) sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
|
Arm II: Resistance Exercise
n=9 participants at risk
ARM II: Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
|
Control Group
n=9 participants at risk
After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
Exercise Intervention: Digital copies and outline of sessions: Receive digital copy of AE and RE sessions and an outline of sessions
Questionnaire Administration: Ancillary studies
Quality-of-Life Assessment: Ancillary studies
|
|---|---|---|---|
|
Gastrointestinal disorders
Any Gastrointestinal/Digestive
|
77.8%
7/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
66.7%
6/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
77.8%
7/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
|
Skin and subcutaneous tissue disorders
Any Skin
|
55.6%
5/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
55.6%
5/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
55.6%
5/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
|
Respiratory, thoracic and mediastinal disorders
Any Respiratory
|
66.7%
6/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
66.7%
6/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
33.3%
3/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
|
Musculoskeletal and connective tissue disorders
Any Musculoskeletal
|
100.0%
9/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
88.9%
8/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
88.9%
8/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
|
Nervous system disorders
Any Neurological
|
100.0%
9/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
100.0%
9/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
77.8%
7/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
|
Psychiatric disorders
Any Psychiatric
|
66.7%
6/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
55.6%
5/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
66.7%
6/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
|
Musculoskeletal and connective tissue disorders
Injury
|
77.8%
7/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
44.4%
4/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
22.2%
2/9 • Adverse events were collected every 2 weeks for all 24 weeks of the intervention.
Every two weeks, all participants were emailed a self-report survey to indicate the presence, severity, interference, and attribution of various medical symptoms
|
Additional Information
Dr. Kerryn Reding, Study Principal Investigator
University of Washington
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place